ArticleOphthalmic plastic and reconstructive surgery
Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.
Article in Ophthalmic plastic and reconstructive surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Efficacy and safety of vismodegib in periocular and orbital basal cell carcinoma: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Efficacy and Safety of Sonic Hedgehog Inhibitors in Basal Cell Carcinomas: An Updated Systematic Review and Meta-analysis (2009-2022).American journal of clinical dermatology · 2023Pooled it
- Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial.JAMA ophthalmology · 2020Trial
- A Systematic Review and Meta-Analysis of Ocular and Periocular Basal Cell Carcinoma with First-Time Description of Dermoscopic and Reflectance Confocal Microscopy Features of Caruncle Basal Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2025Review
- Targeted Drug Delivery in Periorbital Non-Melanocytic Skin Malignancies.Bioengineering (Basel, Switzerland) · 2024Review
- Expression and Functional Analysis of the Smo Protein inInsects · 2024Article
- Vismodegib as an adjuvant treatment for periorbital basal cell carcinoma: a case report and review of literature.Annals of translational medicine · 2024Article
- Advanced Periocular Basal Cell Carcinoma with Orbital Invasion: Update on Management and Treatment Advances.Journal of ophthalmology · 2024Article
- Optimizing the effective doses of mitomycin C, 5-fluorouracil, and their combination on cultivated basal cell carcinoma.Arquivos brasileiros de oftalmologia · 2021Article
- Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib.American journal of ophthalmology case reports · 2020Article
- Periocular basal cell carcinoma - clinical perspectives.Oncology reviews · 2020Article
- [Alternative treatment options for periorbital basal cell carcinoma].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2020Review
- [Advanced periocular basal cell carcinoma-a therapeutic challenge].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2019Article
- Targeting GLI Transcription Factors in Cancer.Molecules (Basel, Switzerland) · 2018Review
- Analysis of hedgehog signaling in periocular sebaceous carcinoma.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2018Observational
- Hedgehog signaling regulates ciliary localization of mouse odorant receptors.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Surgical Management of Periocular Cancers: High- and Low-Risk Features Drive Treatment.Current oncology reports · 2017Review
- Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases.Plastic and reconstructive surgery. Global open · 2017Article
- [Current diagnostics and therapy recommendations for ocular basal cell carcinoma].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2017Review
- Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment.OncoTargets and therapy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
purposeEvaluate the effectiveness of vismodegib in the management of basal cell carcinoma with orbital extension and/or extensive periocular involvement.
methodsRetrospective chart review of 6 consecutive patients with biopsy-proven orbital basal cell carcinoma and 2 additional patients with extensive periocular basal cell carcinoma who were treated with oral vismodegib (150 mg/day) was performed.
resultsBasal cell carcinoma extended in the orbit in 6 of 8 patients (involving orbital bones in 1 patient), and 2 of 8 patients had extensive periocular involvement (1 with basal cell nevus syndrome). Vismodegib therapy was the only treatment in 6 patients, off-label neoadjuvant in 1 patient, and adjuvant treatment in 1 patient. Orbital tumors in all 4 patients who received vismodegib as sole treatment showed partial response with a mean 83% shrinkage in tumor size after a median of 7 months of therapy. In the 2 patients receiving vismodegib as neoadjuvant or adjuvant therapies, there was complete response after a median of 7 months of therapy and no evidence of clinical recurrence after discontinuing therapy for a median of 15 months. The 2 patients with extensive periocular involvement experienced complete clinical response after a median 14 months of treatment. During treatment, the most common side effects were muscle spasm (75%) followed by alopecia (50%), dysgeusia (25%), dysosmia, and episodes of diarrhea and constipation (13%).
conclusionsBasal cell carcinoma with orbital extension and extensive periocular involvement responds to vismodegib therapy. The long-term prognosis remains unknown, and additional prospective studies are indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.